 |
1 Disease |  |
1 Trial |
|
1 Trial |  |
60 News |  |
- | Oxecta (oxycodone) / Assertio, Xtampza ER (oxycodone) / Collegium Pharma
Trial completion, Enrollment change, Trial completion date, Trial primary completion date, Surgery: A Multimodal Analgesia Protocol Adapted for Ambulatory Surgery (clinicaltrials.gov) - Jul 20, 2023
P4, N=100, Completed, Sponsor: University of Utah
Recruiting --> Completed | N=300 --> 100 | Trial completion date: Jul 2021 --> Jan 2023 | Trial primary completion date: Jul 2021 --> Jan 2023
- | Journal: Opioids for pain. (Pubmed Central) - Dec 22, 2022
Recruiting --> Completed | N=300 --> 100 | Trial completion date: Jul 2021 --> Jan 2023 | Trial primary completion date: Jul 2021 --> Jan 2023 No abstract available
- | Journal: Comparison table: Some oral/transdermal opioid analgesics. (Pubmed Central) - Dec 22, 2022
No abstract available No abstract available
- | Oxecta (oxycodone) / Assertio, Xtampza ER (oxycodone) / Collegium Pharma
Trial completion: Are Opioids Needed After ACL Reconstruction (clinicaltrials.gov) - Dec 12, 2022
P4, N=100, Completed, Sponsor: Emory University
No abstract available Recruiting --> Completed
- |||| Oxecta (oxycodone) / Assertio, Xtampza ER (oxycodone) / Collegium Pharma, OxiFast (oxycodone immediate release) / Purdue, Shionogi, Mundipharma
Trial completion date, Trial primary completion date, Monotherapy, Metastases: NanaBis (clinicaltrials.gov) - Apr 12, 2022
P3, N=360, Not yet recruiting, Sponsor: Medlab Clinical
Recruiting --> Completed Trial completion date: Jan 2024 --> Jun 2024 | Trial primary completion date: Aug 2023 --> Feb 2024
- | Trial completion, Trial completion date: Transversus Abdominis Plane Block in Microsurgical Breast Recon w/Abdominal Free Flap in Breast CA (clinicaltrials.gov) - Sep 23, 2021
P3, N=120, Completed, Sponsor: Stanford University
Trial completion date: Jan 2024 --> Jun 2024 | Trial primary completion date: Aug 2023 --> Feb 2024 Recruiting --> Completed | Trial completion date: Mar 2020 --> Jun 2021
- | Oxecta (oxycodone) / Assertio, Xtampza ER (oxycodone) / Collegium Pharma
Enrollment open, Trial completion date, Trial primary completion date: Are Opioids Needed After ACL Reconstruction (clinicaltrials.gov) - May 6, 2021
P4, N=90, Recruiting, Sponsor: Emory University
Recruiting --> Completed | Trial completion date: Mar 2020 --> Jun 2021 Not yet recruiting --> Recruiting | Trial completion date: Apr 2021 --> Nov 2022 | Trial primary completion date: Apr 2021 --> Nov 2022
- |||||||||| Oxecta (oxycodone) / Assertio, Xtampza ER (oxycodone) / Collegium Pharma, OxiFast (oxycodone immediate release) / Purdue, Shionogi, Mundipharma
New P3 trial, Monotherapy, Metastases: NanaBis (clinicaltrials.gov) - Mar 21, 2021
P3, N=360, Not yet recruiting, Sponsor: Medlab Clinical
- Oxecta (oxycodone) / Zyla Life Sciences
[VIRTUAL] The Dorsal Peduncular Cortex is a Cortical Master of Opioid Withdrawal () - Sep 30, 2020 - Abstract #ACNP2020ACNP_294;
The DP shows enriched expression of the µ opioid receptor, and selectively deleting this receptor in the DP reverses the hedonic valence of oxycodone, creating aversion rather than reward. Most interestingly, electrophysiological and single-nuclei sequencing data indicate that this receptor is expressed on glutamatergic output neurons, and anatomical tracing experiments show these neurons projecting to hindbrain regions known to be implicated in addiction and stress responses.
- | Oxecta (oxycodone) / Zyla Life Sciences
Preclinical, Journal: Oxycodone-Mediated Activation of the Mu Opioid Receptor Reduces Whole Brain Functional Connectivity in Mice. (Pubmed Central) - Apr 9, 2020
In conclusion, we demonstrate that oxycodone reduces brain communication in a MOR-dependent manner, and establish a preliminary whole-brain FC signature of oxycodone. This proof-of-principle study provides a unique platform and reference data set to test other MOR opioid agonists and perhaps discover new mechanisms and FC biomarkers predicting safer analgesics.
- | Oxecta (oxycodone) / Zyla Life Sciences
Journal: Dopamine DR antagonist VK4-116 attenuates oxycodone self-administration and reinstatement without compromising its antinociceptive effects. (Pubmed Central) - Apr 1, 2020
In contrast, VK4-116 had little effect on oral sucrose self-administration. Taken together, these findings indicate a central role for D3Rs in opioid reward and support further development of VK4-116 as an effective agent for mitigating the development of opioid addiction, reducing the severity of withdrawal and preventing relapse.
- | Oxecta (oxycodone) / Assertio, Xtampza ER (oxycodone) / Collegium Pharma
New P4 trial: Are Opioids Needed After ACL Reconstruction (clinicaltrials.gov) - Feb 26, 2020
P4, N=90, Not yet recruiting, Sponsor: Emory University
- || Oxecta (oxycodone) / Zyla Life Sciences
Clinical, Review, Journal: Opioid-induced toxic leukoencephalopathy: A case report and review of the literature. (Pubmed Central) - Dec 28, 2019
Reports demonstrate a range of outcomes that include patients who died to those with no residual neurologic deficits. This review of reported pediatric cases of opioid-induced leukoencephalopathy highlights the importance of early neurosurgical intervention for prevention of devastating outcomes.
- | Oxecta (oxycodone) / Assertio, Xtampza ER (oxycodone) / Collegium Pharma
Enrollment open, Surgery: A Multimodal Analgesia Protocol Adapted for Ambulatory Surgery (clinicaltrials.gov) - Nov 15, 2019
P4, N=300, Recruiting, Sponsor: University of Utah
This review of reported pediatric cases of opioid-induced leukoencephalopathy highlights the importance of early neurosurgical intervention for prevention of devastating outcomes. Not yet recruiting --> Recruiting
- Oxecta (oxycodone) / Egalet
Identification of the Dorsal Peduncular Area as a Highly Novel Regulator of Opioid Reward (Floridian Ballroom) - Oct 17, 2019 - Abstract #ACNP2019ACNP_1203;
The DP shows enriched expression of the µ opioid receptor, and most interestingly, electrophysiological and single-nuclei sequencing data indicate that this receptor is expressed on glutamatergic output neurons. Furthermore, the connectivity profile of the DP makes it a highly likely candidate to be an important regulator of opioid reward, analgesia, and withdrawal.
- Oxecta (oxycodone) / Egalet
NOS1 in the Interpeduncular Nucleus Regulates Behavioral Tolerance to Drugs of Abuse (Floridian Ballroom) - Oct 17, 2019 - Abstract #ACNP2019ACNP_448;
Development of addiction proceeds through several stages, including development of tolerance and escalation of dose. Here we provide evidence that NO production in the IPN can regulate behavioral tolerance to multiple drugs of abuse.
- | Gralise (gabapentin) / Alvogen
Phase classification, HEOR: Gabapentin, Methadone Hydrochloride, and Oxycodone Hydrochloride in Improving Quality of Life in Patients With Stage II-IV Head and Neck Cancer During Chemoradiation (clinicaltrials.gov) - Sep 30, 2019
P1, N=60, Completed, Sponsor: Roswell Park Cancer Institute
Here we provide evidence that NO production in the IPN can regulate behavioral tolerance to multiple drugs of abuse. Phase classification: P=N/A --> P1
- | Oxecta (oxycodone) / Assertio, Xtampza ER (oxycodone) / Collegium Pharma
New P4 trial, Surgery: A Multimodal Analgesia Protocol Adapted for Ambulatory Surgery (clinicaltrials.gov) - Jul 10, 2019
P4, N=300, Not yet recruiting, Sponsor: University of Utah
- | Trial completion date, Trial primary completion date: Transversus Abdominis Plane Block in Microsurgical Breast Recon w/Abdominal Free Flap in Breast CA (clinicaltrials.gov) - May 21, 2019
P3, N=128, Recruiting, Sponsor: Stanford University
Phase classification: P=N/A --> P1 Trial completion date: Dec 2019 --> Mar 2020 | Trial primary completion date: Mar 2019 --> Jan 2020
- | Trial completion date, Trial primary completion date: Transversus Abdominis Plane Block in Microsurgical Breast Recon w/Abdominal Free Flap in Breast CA (clinicaltrials.gov) - Feb 11, 2019
P3, N=128, Recruiting, Sponsor: Stanford University
Trial completion date: Dec 2019 --> Mar 2020 | Trial primary completion date: Mar 2019 --> Jan 2020 Trial completion date: Jun 2018 --> Dec 2019 | Trial primary completion date: Jun 2018 --> Mar 2019
- | Gralise (gabapentin) / Alvogen
Trial completion, Trial completion date, Trial primary completion date, HEOR: Gabapentin, Methadone Hydrochloride, and Oxycodone Hydrochloride in Improving Quality of Life in Patients With Stage II-IV Head and Neck Cancer During Chemoradiation (clinicaltrials.gov) - Aug 22, 2018
P=N/A, N=60, Completed, Sponsor: Roswell Park Cancer Institute
Trial completion date: Jun 2018 --> Dec 2019 | Trial primary completion date: Jun 2018 --> Mar 2019 Active, not recruiting --> Completed | Trial completion date: Jan 2022 --> Jun 2018 | Trial primary completion date: Jan 2021 --> Jun 2018
- | Trial primary completion date: Transversus Abdominis Plane Block in Microsurgical Breast Recon w/Abdominal Free Flap in Breast CA (clinicaltrials.gov) - Dec 8, 2017
P3, N=128, Recruiting, Sponsor: Stanford University
Active, not recruiting --> Completed | Trial completion date: Jan 2022 --> Jun 2018 | Trial primary completion date: Jan 2021 --> Jun 2018 Trial primary completion date: Nov 2017 --> Jun 2018
- | Gralise (gabapentin) / Alvogen
Enrollment closed, HEOR: Gabapentin, Methadone Hydrochloride, and Oxycodone Hydrochloride in Improving Quality of Life in Patients With Stage II-IV Head and Neck Cancer During Chemoradiation (clinicaltrials.gov) - Nov 9, 2017
P=N/A, N=60, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
Trial primary completion date: Nov 2017 --> Jun 2018 Recruiting --> Active, not recruiting
- Gralise (gabapentin) / Alvogen
Trial primary completion date, HEOR: Gabapentin, Methadone Hydrochloride, and Oxycodone Hydrochloride in Improving Quality of Life in Patients With Stage II-IV Head and Neck Cancer During Chemoradiation (clinicaltrials.gov) - Nov 29, 2016
P=N/A, N=60, Recruiting, Sponsor: Roswell Park Cancer Institute
Recruiting --> Active, not recruiting Trial primary completion date: Jan 2017 --> Jan 2021
- Gralise (gabapentin) / Alvogen
Enrollment change, HEOR: Gabapentin, Methadone Hydrochloride, and Oxycodone Hydrochloride in Improving Quality of Life in Patients With Stage II-IV Head and Neck Cancer During Chemoradiation (clinicaltrials.gov) - Aug 1, 2016
P=N/A, N=60, Recruiting, Sponsor: Roswell Park Cancer Institute
Trial primary completion date: Jan 2017 --> Jan 2021 N=30 --> 60
- Oxecta (oxycodone) / Assertio
Enrollment change, Trial withdrawal, Trial primary completion date: Clinical Evaluation of the ReLeaf Analgesic Infusion Catheter & Wound Drain (clinicaltrials.gov) - Jan 22, 2016
P=N/A, N=0, Withdrawn, Sponsor: Vital 5, LLC
N=30 --> 60 N=60 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Nov 2016 --> Jan 2016
- || New P3 trial: Transversus Abdominis Plane Block in Microsurgical Breast Recon w/Abdominal Free Flap in Breast CA (clinicaltrials.gov) - Nov 10, 2015
P3, N=128, Recruiting, Sponsor: Stanford University
- Gralise (gabapentin) / Alvogen
New trial, HEOR: Gabapentin, Methadone Hydrochloride, and Oxycodone Hydrochloride in Improving Quality of Life in Patients With Stage II-IV Head and Neck Cancer During Chemoradiation (clinicaltrials.gov) - Aug 25, 2015
P=N/A, N=30, Recruiting, Sponsor: Roswell Park Cancer Institute
- Oxecta (oxycodone) / Assertio
Enrollment open, Trial initiation date, Trial primary completion date: Clinical Evaluation of the ReLeaf Analgesic Infusion Catheter & Wound Drain (clinicaltrials.gov) - Jun 17, 2015
P=N/A, N=60, Recruiting, Sponsor: Vital 5, LLC
N=60 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Nov 2016 --> Jan 2016 Not yet recruiting --> Recruiting | Initiation date: Nov 2014 --> Jun 2015 | Trial primary completion date: Nov 2015 --> Nov 2016
- Oxecta (oxycodone) / Assertio
Clinical: Clinical Evaluation of the ReLeaf Analgesic Infusion Catheter & Wound Drain (clinicaltrials.gov) - Nov 18, 2014
P=N/A, N=60, Not yet recruiting, Sponsor: Vital 5, LLC
- | Nucynta (tapentadol) / Collegium Pharma, Grunenthal
Trial completion: Comparison of the Effects of Tapentadol and Oxycodone on Gastrointestinal and Colonic Transit in Humans (clinicaltrials.gov) - Jan 25, 2012
P4, N=38, Completed, Sponsor: Mayo Clinic
Not yet recruiting --> Recruiting | Initiation date: Nov 2014 --> Jun 2015 | Trial primary completion date: Nov 2015 --> Nov 2016 Recruiting --> Completed
- | Nucynta (tapentadol) / Collegium Pharma, Grunenthal
New P4 trial: Comparison of the Effects of Tapentadol and Oxycodone on Gastrointestinal and Colonic Transit in Humans (clinicaltrials.gov) - Dec 26, 2011
P4, N=38, Completed, Sponsor: Mayo Clinic